The use of immunotherapy for the treatment of tuberculosis

References

• WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.
   Google Scholar
• Kumar A, Kumar AMV, Gupta D, et al. Global guidelines for treatment of tuberculosis among persons living with HIV: unresolved issues. Int J Tuberc Lung Dis. 2012;16:573–578.
   PubMed Web of Science ®Google Scholar
• Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. Infect Dis Rep. 2016;8:33–37.
   Web of Science ®Google Scholar
• Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3:37–49.
   PubMedGoogle Scholar
• Bouchikh S, Stirnemann J, Prendki V, et al. Treatment duration of extra-pulmonary tuberculosis: 6 months or more? TB-INFO database analysis. Rev Med Interne. 2012;33:665–671.
   PubMed Web of Science ®Google Scholar
• Mendonca AMC, Kritski AL, Land MGP, et al. Abandonment of treatment for latent tuberculosis infection and socioeconomic factors in children and adolescents: Rio de Janeiro, Brazil. PLoS ONE. 2016;11:e0154843.
   PubMed Web of Science ®Google Scholar
• Mcgrath M, Gey Van Pittius NC, Van Helden PD, et al. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemoth. 2014;69:292–302.
   PubMed Web of Science ®Google Scholar
• Lauzardo M, Peloquin CA. Tuberculosis therapy for 2016 and beyond. Expert Opin Pharmacother. 2016;17:1859–1872.
   PubMed Web of Science ®Google Scholar
• Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis. 2015;6:170–184.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang B, Hu M, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61:e00239–17.
   PubMed Web of Science ®Google Scholar
• Manohar A, Ahuja J, Crane JK. Immunotherapy for infectious diseases: past, present, and future. Immunol Invest. 2015;44:731–737.
   PubMed Web of Science ®Google Scholar
• Abate G, Hoft DF. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther. 2016;5:37–45.
   PubMed Web of Science ®Google Scholar
• Doherty TM. Immunotherapy for TB. Immunotherapy. 2012;4:629–647.
   PubMed Web of Science ®Google Scholar
• Harriff MJ, Cansler ME, Toren KG, et al. Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8+ T Cells. PLoS ONE. 2014;9:e97515.
   PubMed Web of Science ®Google Scholar
• Rothchild AC, Stowell B, Goyal G, et al. Role of granulocyte-macrophage colony-stimulating factor production by T cells during Mycobacterium tuberculosis infection. MBio. 2017;8:e01514–17.
   PubMed Web of Science ®Google Scholar
• Roberts LL, Robinson CM. Mycobacterium tuberculosis infection of human dendritic cells decreases integrin expression, adhesion and migration to chemokines. Immunology. 2013;141:39–51.
   Web of Science ®Google Scholar
• Khan N, Vidyarthi A, Pahari S, et al. Signaling through NOD-2 and TLR-4 bolsters the t cell priming capability of dendritic cells by inducing autophagy. Sci Rep. 2016;6:19084.
   PubMed Web of Science ®Google Scholar
• Carmona J, Cruz A, Moreira-Teixeira L, et al. Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS ONE. 2013;8:1–10.
   Google Scholar
• Zhao X, Khan N, Gan H, et al. Bcl-xL mediates RIPK3-dependent necrosis in M. tuberculosis - infected macrophages. Mucosal Immunol. 2017;10:1553–1568.
   PubMed Web of Science ®Google Scholar
• Verrall AJ, Gm N, Alisjahbana B, et al. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology. 2014;141:506–513.
   PubMed Web of Science ®Google Scholar
• Roca FJ, Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell. 2013;153:521–534.
   PubMed Web of Science ®Google Scholar
• Cambier CJ, O’Leary SM, O’Sullivan MP, et al. Phenolic glycolipid facilitates mycobacterial escape from microbicidal tissue-resident macrophages. Immunity. 2017;47:552–565.
   PubMed Web of Science ®Google Scholar
• Gideon HP, Phuah JY, Myers AJ, et al. Variability in tuberculosis granuloma t cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathog. 2015;11:e1004603.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ernst JD. Cutting edge: direct recognition of infected cells by CD4 T cells is required for control of intracellular Mycobacterium tuberculosis in vivo. J Immunol. 2013;191:1016–1020.
   PubMed Web of Science ®Google Scholar
• Slight SR, Rangel-Moreno J, Gopal R, et al. CXCR5 + T helper cells mediate protective immunity against tuberculosis. J Clin Invest. 2013;123:1–15.
   PubMed Web of Science ®Google Scholar
• Green AM, DiFazio R, Flynn JL. IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol. 2013;190:270–277.
   PubMed Web of Science ®Google Scholar
• Sakai S, Kauffman KD, Sallin MA, et al. CD4 T cell-derived IFN-γ plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by pd-1 to prevent Lethal Disease. PLoS Pathogens. 2016;12:e1005667.
   PubMed Web of Science ®Google Scholar
• Allie N, Grivennikov SI, Keeton R, et al. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci Rep. 2013;3:1809.
   PubMed Web of Science ®Google Scholar
• Rook GAW. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med. 2007;7:327–337.
   PubMed Web of Science ®Google Scholar
• Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev. 2010;21:455–462.
   PubMed Web of Science ®Google Scholar
• Nouailles G, Dorhoi A, Koch M, et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest. 2014;124:1268–1282.
   PubMed Web of Science ®Google Scholar
• Rivas-Santiago B, Sada E, Tsutsumi V, et al. β-Defensin gene expression during the course of experimental tuberculosis infection. J Infect Dis. 2006;194:697–701.
   PubMed Web of Science ®Google Scholar
• Castañeda-Delgado J, Hernández-Pando R, Serrano CJ, et al. Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol. 2010;161:542–550.
   PubMed Web of Science ®Google Scholar
• Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30:131–141.
   PubMed Web of Science ®Google Scholar
• Arranz-Trullén J, Lu L, Pulido D, et al. Host antimicrobial peptides: the promise of new treatment strategies against tuberculosis. Front Immunol. 2017;8:1499.
   Web of Science ®Google Scholar
• Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–1773.
   PubMed Web of Science ®Google Scholar
• Martineau AR, Wilkinson KA, Newton SM, et al. IFN-γ- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of Cathelicidin LL-37. J Immunol. 2007;178:7190–7198.
   PubMed Web of Science ®Google Scholar
• Ralph AP, Waramori G, Pontororing GJ, et al. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS ONE. 2013;8:e70032.
   PubMed Web of Science ®Google Scholar
• Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care. 2009;179:843–850.
   PubMed Web of Science ®Google Scholar
• Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242–250.
   PubMed Web of Science ®Google Scholar
• Daley P, Jagannathan V, John KR, et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15:528–534.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Zumla A. Vitamin D as adjunctive host-directed therapy in tuberculosis: a systematic review. Open Forum Infect Dis. 2016;3:1–7.
   Web of Science ®Google Scholar
• Coussens AK, Wilkinson RJ, Martineau AR. Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3. PLoS Pathog. 2015;11:1–23.
   Web of Science ®Google Scholar
• Steinmann J, Halldórsson S, Agerberth B, et al. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother. 2009;53:5127–5133.
   PubMed Web of Science ®Google Scholar
• Fehlbaum P, Rao M, Zasloff M, et al. An essential amino acid induces epithelial β-defensin expression. Proc Natl Acad Sci USA. 2000;97:12723–12728.
   PubMed Web of Science ®Google Scholar
• Rivas-Santiago CE, Rivas-Santiago B, León DA, et al. Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin Exp Immunol. 2011;164:80–89.
   PubMed Web of Science ®Google Scholar
• Rivas-Santiago B, Rivas Santiago CE, Sada E, et al. Prophylactic potential of defensins and L-isoleucine in tuberculosis household contacts: an experimental model. Immunotherapy. 2015;7:207–213.
   PubMed Web of Science ®Google Scholar
• Llamas-Gonzalez YY, Pedroza-Roldan C, Cortes-Serna MB, et al. The synthetic cathelicidin HHC-10 inhibits mycobacterium bovis BCG in vitro and in C57BL/6 mice. Microb Drug Resist. 2013;19:124–129.
   PubMed Web of Science ®Google Scholar
• Rivas-Santiago B, Castañeda-Delgado JE, Rivas Santiago CE, et al. Ability of innate defence regulator peptides idr-1002, idr-hh2 and idr-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS ONE. 2013;8:e59119.
   PubMedGoogle Scholar
• Rivas-Santiago B, Rivas Santiago CE, Castañeda-Delgado JE, et al. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Ag. 2013;41:143–148.
   PubMed Web of Science ®Google Scholar
• Silva JP, Gonçalves C, Costa C, et al. Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment. J Control Release. 2016;235:112–124.
   PubMed Web of Science ®Google Scholar
• Clifford V, Tebruegge M, Zufferey C, et al. Mycobacteria-specific cytokine responses as correlates of treatment response in active and latent tuberculosis. J Infect. 2017;75:132–145.
   PubMed Web of Science ®Google Scholar
• Tebruegge M, Dutta B, Donath S, et al. Mycobacteria-specific cytokine responses detect tuberculosis infection and distinguish latent from active tuberculosis. Am J Resp Crit Care. 2015;192:485–499.
   PubMed Web of Science ®Google Scholar
• Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010;125:S53–S72.
   PubMed Web of Science ®Google Scholar
• Denis M, Ghadirian E. Immunotherapy of airborne tuberculosis in mice via the lung-specific delivery of cytokines. Can J Infect Dis. 1993;4:38–42.
   PubMedGoogle Scholar
• Reljic R. IFN-γ therapy of tuberculosis and related infections. J Interf Cytok Res. 2007;27:353–364.
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet. 1997;349:1513–1515.
   PubMed Web of Science ®Google Scholar
• Gao X-F, Z-W Yang, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis. 2011;15:e594–e600.
   PubMed Web of Science ®Google Scholar
• Giosuè S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-α in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 1998;158:1156–1162.
   PubMed Web of Science ®Google Scholar
• Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, et al. Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor. Med Oncol. 2014;31:774.
   Web of Science ®Google Scholar
• Berretta F, St-Pierre J, Piccirillo CA, et al. IL-2 contributes to maintaining a balance between CD4+foxp3+ regulatory t cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. J Immunol. 2011;186:4862–4871.
   PubMed Web of Science ®Google Scholar
• Zhang YR, Liu J, Wang Y, et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci. 2012;55:800–806.
   PubMed Web of Science ®Google Scholar
• Toossi Z, Kleinhenz ME, Ellner JJ. Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis. J Exp Med. 1986;163:1162–1172.
   PubMed Web of Science ®Google Scholar
• Johnson BJ, Bekker L-G, Rickman R, et al. rhulL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis. 1997;78:195–203.
   PubMedGoogle Scholar
• Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci. 2015;11:584–590.
   PubMed Web of Science ®Google Scholar
• Denis M, Gregg EO, Ghandirian E. Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages. Int J Immunopharmacol. 1990;12:721–727.
   PubMed Web of Science ®Google Scholar
• Pedral-Sampaio DB, Netto EM, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis. 2003;7:245–252.
   PubMedGoogle Scholar
• Horn T, Burke P, Karp J, et al. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol. 1991;127:49–52.
   PubMedGoogle Scholar
• Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines-from host defence to tissue homeostasis. Nat Rev Immunol. 2014;14:783–795.
   PubMed Web of Science ®Google Scholar
• Behrends J, Renauld JC, Ehlers S, et al. IL-22 is mainly produced by IFNγ-secreting cells but is dispensable for host protection against Mycobacterium tuberculosis infection. PLoS ONE. 2013;8:37–40.
   Google Scholar
• Dhiman R, Periasamy S, Barnes PF, et al. NK1.1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. J Immunol. 2012;189:897–905.
   PubMed Web of Science ®Google Scholar
• Zeng G, Chen CY, Huang D, et al. Membrane-bound il-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T Cells. J Immunol. 2011;187:190–199.
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen HD, Wang Y, et al. Interleukin 24 as a novel potential cytokine immunotherapy for the treatment of Mycobacterium tuberculosis infection. Microbes Infect. 2011;13:1099–1110.
   PubMed Web of Science ®Google Scholar
• Mata-Espinosa DA, Mendoza-Rodríguez V, Aguilar-León D, et al. Therapeutic effect of recombinant adenovirus encoding interferon-γ in a murine model of progressive pulmonary tuberculosis. Mol Ther. 2008;16:1065–1072.
   Web of Science ®Google Scholar
• Francisco-Cruz A, Mata-Espinosa D, Ramos-Espinosa O, et al. Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis. Tuberculosis. 2016;100:5–14.
   PubMed Web of Science ®Google Scholar
• Ramos-Espinosa O, Hernández-Bazán S, Francisco-Cruz A, et al. Gene therapy based in antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis. Pathog Dis. 2016;74:1–8.
   Web of Science ®Google Scholar
• Hernandez-Pando R, Orozco HE, Sampieri A, et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology. 1996;89:26–33.
   PubMed Web of Science ®Google Scholar
• Hernandez-Pando R, Orozco HE, Arriaga K, et al. Analysis of the local kinetics and localization of interleukin-lα, tumour necrosis factor-a and transforming growth factor-β, during the course of experimental pulmonary tuberculosis. Immunology. 1997;90:607–617.
   PubMed Web of Science ®Google Scholar
• Francisco-Cruz A, Mata-Espinosa D, Estrada-Parra S, et al. Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol. 2013;171:283–297.
   PubMed Web of Science ®Google Scholar
• Glatman-Freedman A. The role of antibodies against TB. In: Norazmi M-N, Acosta A, Sarmiento ME, editors. The art & science of tuberculosis vaccine development. 2nd ed. Selangor Darul Ehsan, Malaysia: Oxford Fajar Sdn Bhd; 2010. p. 238–273.
   Google Scholar
• Teitelbaum R, Glatman-Freedman A, Chen B, et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA. 1998;95:15688–15693.
   PubMed Web of Science ®Google Scholar
• Hamasur B, Haile M, Pawlowski A, et al. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F (ab’)2 fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol. 2004;138:30–38.
   PubMed Web of Science ®Google Scholar
• Williams A, Reljic R, Naylor I, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 2004;111:328–333.
   PubMed Web of Science ®Google Scholar
• López Y, Yero D, Falero-Diaz G, et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol. 2009;299:447–452.
   PubMed Web of Science ®Google Scholar
• Olivares N, León A, López Y, et al. The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis. 2006;86:268–272.
   PubMed Web of Science ®Google Scholar
• Stadlmann J, Pabst M, Altmann F. Analytical and functional aspects of antibody sialylation. J Clin Immunol. 2010;30:S15–S19.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 2005;310:1510–1512.
   PubMed Web of Science ®Google Scholar
• Parekh R, Isenberg D, Rook G, et al. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun. 1989;2:101–114.
   PubMed Web of Science ®Google Scholar
• McCulloch J, Zhang Y, Dawson M, et al. Glycosylation of lgG during potentially arthritogenic lentiviral infections. Rheumatol Int. 1995;14:243–248.
   PubMed Web of Science ®Google Scholar
• Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA. 1994;91:6123–6127.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011;108:12669–12674.
   PubMed Web of Science ®Google Scholar
• Lu LL, Chung AW, Rosebrock T, et al. A functional role for antibodies in tuberculosis. Cell. 2016;167:433–443.
   PubMed Web of Science ®Google Scholar
• Olivares N, Marquina B, Mata-Espinoza D, et al. The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation. Pathog Dis. 2013;69:176–183.
   PubMed Web of Science ®Google Scholar
• Olivares N, Rodriguez Y, Zatarain-Barron ZL, et al. A significant therapeutic effect of immunoglobulins administered alone, or in combination with conventional chemotherapy, in experimental pulmonary tuberculosis caused by drug-sensitive or drug-resistant strains. Pathog Dis. 2017;75:1–8.
   Web of Science ®Google Scholar
• Buccheri S, Reljic R, Caccamo N, et al. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol. 2007;37:729–737.
   PubMed Web of Science ®Google Scholar
• Beamer GL, Flaherty DK, Assogba BD, et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol. 2009;181:5545–5550.
   Web of Science ®Google Scholar
• Segueni N, Tritto E, Bourigault M, et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralization. Sci Rep. 2016;6:36923.
   PubMedGoogle Scholar
• Shen L, Shi H, Gao Y, et al. The characteristic pro fi les of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis. Tuberculosis. 2016;101:146–150.
   PubMed Web of Science ®Google Scholar
• Singh A, Mohan A, Dey AB, et al. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis – specific interferon γ – producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. 2013;208:603–615.
   PubMed Web of Science ®Google Scholar
• Toossi Z, Gogate P, Shiratsuchi H, et al. Enhanced production of TGF-β by blood monocytes from patients with active tuberculosis and presence of TGF-β in tuberculous granulomatous lung lesions. J Immunol. 1995;154:465–473.
   PubMed Web of Science ®Google Scholar
• Hernández-Pando R, Orozco-Esteves H, Maldonado H, et al. A combination of a transforming growth factor-β antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol. 2006;144:264–272.
   PubMed Web of Science ®Google Scholar
• Stanford JL, Bahr GM, Rook GAW, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle. 1990;71:87–93.
   PubMedGoogle Scholar
• Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med. 2002;8:625–629.
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med. 2010;83:209–215.
   PubMedGoogle Scholar
• Dlugovitzky D, Fiorenza G, Farroni M, et al. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Resp Med. 2006;100:1079–1087.
   PubMed Web of Science ®Google Scholar
• Dlugovitzky D, Notario R, Martinel-Lamas D, et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy. 2010;2:159–169.
   PubMed Web of Science ®Google Scholar
• Vilaplana C, Gil O, Cáceres N, et al. Prophylactic effect of a therapeutic vaccine against tb based on fragments of Mycobacterium tuberculosis. PLoS ONE. 2011;6:2–6.
   Web of Science ®Google Scholar
• Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase i clinical trial of the therapeutical antituberculous vaccine RUTI®. Vaccine. 2010;28:1106–1116.
   PubMed Web of Science ®Google Scholar
• Pj C. RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis. 2006;86:273–289.
   PubMed Web of Science ®Google Scholar
• Nell AS, D’Lom E, Bouic P, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS ONE. 2014;9:e89612.
   PubMed Web of Science ®Google Scholar
• Hernández-Pando R, Streber MDLL, Orozco H, et al. The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice. Immunology. 1998;95:234–241.
   PubMed Web of Science ®Google Scholar
• Hernández-Pando R, De La Luz Streber M, Orozco H, et al. Emergent immunoregulatory properties of combined glucocorticoid and anti-glucocorticoid steroids in a model of tuberculosis. Q J Med. 1998;91:755–766.
   Google Scholar
• Hernández-Pando R, Aguilar-Leon D, Orozco H, et al. 16α-Bromoepiandrosterone restores t helper cell type 1 activity and accelerates chemotherapy- induced bacterial clearance in a model of progressive pulmonary tuberculosis. J Infect Dis. 2005;191:299–306.
   PubMed Web of Science ®Google Scholar
• Stickney DR, Noveljic Z, Garsd A, et al. Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. Antimicrob Agents Chemother. 2007;51:2639–2641.
   PubMed Web of Science ®Google Scholar
• Reading C, Dowding C, Schramm B, et al. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16α-bromoepiandrosterone (HE2000). Clin Microbiol Infect. 2006;12:1082–1088.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ke X, Khara JS, et al. Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity. Biomaterials. 2014;35:3102–3109.
   PubMed Web of Science ®Google Scholar
• Yuan XL, Wen Q, De NM, et al. Immune formulation-assisted conventional therapy on anti-infective effectiveness of multidrug-resistant Mycobacterium tuberculosis infection mice. Asian Pac J Trop Med. 2016;9:293–297.
   PubMed Web of Science ®Google Scholar
• Parida SK, Madansein R, Singh N, et al. Cellular therapy in tuberculosis. Int J Infect Dis. 2015;32:32–38.
   PubMed Web of Science ®Google Scholar
• Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19:667–679.
   PubMed Web of Science ®Google Scholar
• Duffy MM, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Therapy. 2011;2:34.
   Web of Science ®Google Scholar
• Raghuvanshi S, Sharma P, Singh S, et al. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci USA. 2010;107:21653–21658.
   PubMed Web of Science ®Google Scholar
• Khan A, Mann L, Papanna R, et al. Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. Sci Rep. 2017;7:1–15.
   PubMedGoogle Scholar
• Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med. 2014;2:108–122.
   PubMed Web of Science ®Google Scholar
• Skrahin A, Jenkins HE, Hurevich H, et al. Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2016;4:21–27.
   PubMedGoogle Scholar
• Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673–684.
   PubMed Web of Science ®Google Scholar
• Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181–187.
   PubMed Web of Science ®Google Scholar
• Ping X, Junchi X, Xinnian C, et al. Autologous cytokine-induced killer (CIK) immunotherapy in a case of disseminated tuberculosis. Sarcoidosis Vasc Diffuse. 2015;32:83–86.
   PubMed Web of Science ®Google Scholar
• Castillo EF, Dekonenko A, Arko-Mensah J, et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci USA. 2012;109:E3168–E3176.
   PubMed Web of Science ®Google Scholar
• Singh P, Subbian S. Harnessing the mTOR pathway for tuberculosis treatment. Front Microbiol. 2018;9:1–11.
   PubMed Web of Science ®Google Scholar
• Rao M, Valentini D, Zumla A, et al. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. Int J Infect Dis. 2018;69:78–84.
   PubMed Web of Science ®Google Scholar
• Gupta S, Cheung L, Pokkali S, et al. Suppressor cell-depleting immunotherapy with denileukin diftitox is an effective host-directed therapy for tuberculosis. J Infect Dis. 2017;215:1883–1887.
   PubMed Web of Science ®Google Scholar